AMZN
Amazon.com, Inc.
AMZN has a slight edge over BROS overall, supported by lower modeled downside.
BROS
Dutch Bros Inc.
BROS offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
BROS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
BROS's revenue, profitability, cash flow and balance sheet are all currently healthy.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN's PE is in its cheap range at 22x, but its recent earnings include one-off gains. On analysts' estimates for next year's earnings, today's price would be 27x.
BROS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 31x | $33.71 | — |
| Current | 43x | $33.71 | — |
| Cheap | 88x | $68.51 | +103% |
| Fair | 162x | $126 | +275% |
| Expensive | 567x | $442 | +1213% |
Historical ranges are pointers, not guarantees.
BROS has the edge over AMZN in the historical PE scenario, which offers more potential upside but is not a forecast.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
Analysts expect earnings and revenue growth for AMZN, with profitability improving.
BROS Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for BROS, with profitability holding steady. However, they disagree widely on these estimates.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN's earnings per share have climbed steadily: $12.37 over the past year, up 75% from the year before, and higher year over year for 14 quarters in a row. Its recent earnings include one-off gains.
BROS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.10 | +41% |
| Q3 2026 | $0.78 | +56% |
| Q2 2026 | $0.72 | +53% |
| Q1 2026 | $0.64 | +64% |
| Q4 2025 | $0.64 | +88% |
| Q3 2025 | $0.50 | +72% |
| Q2 2025 | $0.47 | +88% |
| Q1 2025 | $0.39 | +117% |
| Q4 2024 | $0.34 | +1033% |
BROS has the edge over AMZN on earnings, with stronger typical year-over-year growth.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
AMZN's revenue has grown year over year every quarter since late 2020: $202B last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN has the edge over BROS on profitability, with a higher operating margin.
BROS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $549.8M | +30% |
| Q2 2026 | $550.9M | +32% |
| Q1 2026 | $464.4M | +31% |
| Q4 2025 | $443.6M | +29% |
| Q3 2025 | $423.6M | +25% |
| Q2 2025 | $415.8M | +28% |
| Q1 2025 | $355.2M | +29% |
| Q4 2024 | $342.8M | +35% |
BROS has the edge over AMZN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.6% | -0.2 points |
| Q2 2026 | 13% | -0.4 points |
| Q1 2026 | 7.4% | -1.4 points |
| Q4 2025 | 7.7% | +3.1 points |
| Q3 2025 | 9.8% | +0.2 points |
| Q2 2025 | 13% | +3.2 points |
| Q1 2025 | 8.8% | -0.6 points |
| Q4 2024 | 4.6% | +3.7 points |
BROS's operating margin was 9.6% last quarter, about level with the same quarter a year ago.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
AMZN's free cash flow was −$46.9B over the past year, against $10.6B the year before.
BROS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $14.8M | -22% |
| Q2 2026 | $39.9M | +12% |
| Q1 2026 | $27.7M | +$36.4M |
| Q4 2025 | $8.5M | -56% |
| Q3 2025 | $18.9M | -28% |
| Q2 2025 | $35.7M | +$40.6M |
| Q1 2025 | -$8.7M | +$7.6M |
| Q4 2024 | $19.5M | +$35.2M |
BROS has the edge over AMZN on cash generation, producing positive trailing cash flow while its opponent burns cash.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has the edge over BROS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
BROS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.5% | +3.4M shares |
| 1 year | +8.5% | +10.8M shares |
| 3 years | +141% | +80.8M shares |
| 5 years | +195% | +91.4M shares |
| Available history | +181% | +89.1M shares |
BROS has 138M diluted shares, up 8.5% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q4 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
BROS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.0x | Very low |
| Q2 2026 | -0.2x | Net Cash |
| Q1 2026 | -0.2x | Net Cash |
| Q4 2025 | -0.3x | Net Cash |
| Q3 2025 | -0.3x | Net Cash |
| Q2 2025 | -0.2x | Net Cash |
| Q1 2025 | -0.2x | Net Cash |
| Q4 2024 | -0.3x | Net Cash |
BROS has the edge over AMZN on leverage, with a lower net debt burden relative to earnings.
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
BROS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.1 | Neutral |
| Stochastic | 8.2 | Oversold |
BROS's weekly RSI is 31 (neutral) and its Stochastic is 8 (oversold).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN has the edge over BROS on valuation relative to its sector.
BROS PE vs Consumer Cyclical Sector
| Metric | BROS | Sector median | Relative |
|---|---|---|---|
| PE | 43x | 18x | 140% above |
| PE % | 0 | 57 | 57 pts below |
BROS is trading at 43x earnings, a 140% premium to the Consumer Cyclical sector's median of 18x.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN has the edge over BROS on trend strength, trading above more of its moving averages.
BROS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $38.5 | 12% below |
| 20 week MA | $49.0 | 31% below |
| 50 week MA | $53.8 | 37% below |
| 100 week MA | $58.1 | 42% below |
| 200 week MA | $45.3 | 26% below |
BROS is in a downtrend: it's below all five of its weekly moving averages, and 26% below its 200-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has the edge over BROS on returns for 2026, with the stronger performance.
BROS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $43.6 | $52.9 | +21% |
| 2022 | $52.9 | $30.1 | -43% |
| 2023 | $30.1 | $31.7 | +5.3% |
| 2024 | $31.7 | $53.4 | +68% |
| 2025 | $53.4 | $64.0 | +20% |
| 2026 YTD | $64.0 | $33.7 | -47% |
BROS is down 47% so far in 2026, after finishing higher in four of the previous five years.